Ascendis Pharma A/S (ASND) stock: insider trades, news & valuation
Health Care · Net sellingShare price and insider trades
Ascendis Pharma A/S insider trading at a glance (Oct 9, 2026): in the past 12 months, 2 insiders bought $777K and 3 sold $5.5M of ASND stock on the open market; P/E 17.1 vs. a sector median of 24.7.
Get emailed when insiders cluster-buy stocks like ASND
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
ASND insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | $493K | 2 | $873K | 2 |
| Q2 2026 | $284K | 7 | $4.6M | 1 |
Valuation, profit and volume
Summary
Over the past 12 months, 2 Ascendis Pharma A/S insiders reported open-market purchases totaling $777K, while 3 insiders reported sales totaling $5.5M. Among insiders with enough purchase history to measure, Scott Thomas Smith (CFO) has the highest Insider Score at 79. 0 of 3 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 9SEC | Mads BodenhoffSvp & Pao | Sell | 3,000 | $270.19 | $811K | -15.2% | — |
| Sep 3SEC | Lars HoltugDirector | Sell | 2364,000 held (−6%) | $264.13 | $62K | -13.2% | — |
| Aug 18SEC | Jean Jacques BienaimeDirector | Buy | 1,1002,000 held (+122%) | $245.85 | $270K | -6.8% | 66 |
| Aug 18SEC | Jean Jacques BienaimeDirector | Buy | 9002,900 held (+45%) | $246.91 | $222K | -7.2% | 66 |
| Jun 2SEC | Scott Thomas SmithCFO | Buy | 1004,367 held (+2%) | $219.00 | $22K | +4.7% | 79 |
| Jun 1SEC | Scott Thomas SmithCFO | Buy | 2504,267 held (+6%) | $223.32 | $56K | +2.6% | 79 |
| Jun 1SEC | Jean Jacques BienaimeDirector | Buy | 200600 held (+50%) | $223.76 | $45K | +2.4% | 66 |
| Jun 1SEC | Jean Jacques BienaimeDirector | Buy | 200800 held (+33%) | $222.30 | $44K | +3.1% | 66 |
| Jun 1SEC | Jean Jacques BienaimeDirector | Buy | 100900 held (+12%) | $223.50 | $22K | +2.6% | 66 |
| May 27SEC | Jean Jacques BienaimeDirector | Buy | 200400 held (+100%) | $239.37 | $48K | -4.2% | 66 |
| May 27SEC | Jean Jacques BienaimeDirector | Buy | 200new position | $236.24 | $47K | -3.0% | 66 |
| May 12SEC | Flemming Steen JensenSee Remarks | Sell | 19,460 | $238.49 | $4.6M | -3.9% | — |
Insiders at Ascendis Pharma A/S
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Flemming Steen JensenSee Remarks | — | $4.6M | May 12, 2026 | — |
| Jean Jacques BienaimeDirector | $699K | — | Aug 18, 2026 | 66 |
| Mads BodenhoffSvp & Pao | — | $811K | Sep 9, 2026 | — |
| Scott Thomas SmithCFO | $78K | — | Jun 2, 2026 | 79 |
| Lars HoltugDirector | — | $62K | Sep 3, 2026 | — |
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
ASND stock: common questions
Are Ascendis Pharma A/S insiders buying ASND stock?
In the past 12 months, 2 insiders reported open-market purchases of ASND worth $777K. The latest was Director Jean Jacques Bienaime bought $270K of ASND at $245.85 — largest purchase by this insider in our records; raises the stake by 122%.
Are Ascendis Pharma A/S insiders selling ASND stock?
3 insiders reported sales worth $5.5M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is ASND's P/E ratio?
ASND trades at about 17.1 times trailing earnings, compared with a median of 24.7 for the Health Care sector.
What is ASND's 52-week range?
Over the past year ASND has traded between $196.01 and $277.18. It last closed at $229.23 on Oct 9, 2026.